| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
J Am Dent Assoc, Vol 136, No 12, 1658-1668.
© 2005 American Dental Association |  |
COVER STORY |
An American Academy of Oral Medicine position paper
Background. This position paper addresses the prevention of bisphosphonate-associated osteonecrosis (BON) and the management of care of patients with cancer and/or osteoporosis who are receiving bisphosphonates and who have BON or are at risk of developing it.
Methods. The authors reviewed the literature available on this newly described oral complication. Information of interest included bisphosphonates, the medications associated with this oral complication; the patient population at risk of developing BON and the diseases being treated with this class of medications; the clinical presentation of the oral lesions; guidelines for managing the care of patients who develop BON; the prevention of this complication based on current knowledge; and recommendations for routine dental treatment of patients receiving bisphosphonates.
Results. There is strong evidence that bisphosphonate therapy is the common link in patients with BON. The pathobiological mechanism leading to BON may have to do with the inhibition of bone remodeling and decreased intraosseous blood flow caused by bisphosphonates. People at risk include patients with multiple myeloma and patients with cancer metastatic to bone who are receiving intravenous bisphosphonates, as well as patients taking bisphosphonates for osteoporosis. The risk of developing complications appears to increase with time of use of the medication. There are no guidelines based on evidence, and the clinical management of the oral complication is based on expert opinion.
Conclusion. Prevention of BON is the best approach to management of this complication. Existing protocols to manage the care of patients who will receive radiation therapy or chemotherapy may be used until specific guidelines for BON are developed.
This article has been cited by other articles:
|
|
 |
|
  S. A. Almazrooa and S.-B. Woo Bisphosphonate and Nonbisphosphonate-Associated Osteonecrosis of the Jaw: A Review J Am Dent Assoc, July 1, 2009; 140(7): 864 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Aronson When I Use a word ... Changing your practice QJM, May 21, 2009; (2009) hcp055v1. [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. KHAN, G. K.B. SANDOR, E. DORE, A. D. MORRISON, M. ALSAHLI, F. AMIN, E. PETERS, D. A. HANLEY, S. R. CHAUDRY, B. LENTLE, et al. Bisphosphonate Associated Osteonecrosis of the Jaw J Rheumatol, March 1, 2009; 36(3): 478 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. CAMPISI, S. FEDELE, G. COLELLA, A. L. CASTO, and V. FUSCO To the Editor J Rheumatol, February 1, 2009; 36(2): 451 - 452. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken Bisphosphonates in Oncology: Rising Stars or Fallen Heroes Oncologist, February 1, 2009; 14(2): 181 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I. Ripamonti, M. Maniezzo, T. Campa, E. Fagnoni, C. Brunelli, G. Saibene, C. Bareggi, L. Ascani, and E. Cislaghi Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan Ann. Onc., January 1, 2009; 20(1): 137 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Dimopoulos, E. Kastritis, C. Bamia, I. Melakopoulos, D. Gika, M. Roussou, M. Migkou, E. Eleftherakis-Papaiakovou, D. Christoulas, E. Terpos, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann. Onc., January 1, 2009; 20(1): 117 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mariotti Bisphosphonates and Osteonecrosis of the Jaws J Dent Educ., August 1, 2008; 72(8): 919 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Estilo, C. H. Van Poznak, T. Wiliams, G. C. Bohle, P. T. Lwin, Q. Zhou, E. R. Riedel, D. L. Carlson, H. Schoder, A. Farooki, et al. Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy Oncologist, August 1, 2008; 13(8): 911 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Edwards and C. A. Migliorati Osteoporosis and Its Implications for Dental Patients J Am Dent Assoc, May 1, 2008; 139(5): 545 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Jadu, L. Lee, M. Pharoah, D. Reece, and L. Wang A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients Ann. Onc., December 1, 2007; 18(12): 2015 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.L. Ruggiero and S.J. Drew Osteonecrosis of the Jaws and Bisphosphonate Therapy Journal of Dental Research, November 1, 2007; 86(11): 1013 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Siegel, C. A. Migliorati, I. Velez, and M. Forrest Exposed bone in the palate J Am Dent Assoc, October 1, 2007; 138(10): 1341 - 1343. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Adornato, I. Morcos, and J. Rozanski The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors J Am Dent Assoc, July 1, 2007; 138(7): 971 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kumar, B. Pass, S. A. Guttenberg, J. Ludlow, R. W. Emery, D. A. Tyndall, and R. J. Padilla Bisphosphonate-related osteonecrosis of the jaws: A report of three cases demonstrating variability in outcomes and morbidity J Am Dent Assoc, May 1, 2007; 138(5): 602 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Khamaisi, E. Regev, N. Yarom, B. Avni, E. Leitersdorf, I. Raz, and S. Elad Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1172 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D Krueger, P. M West, M. Sargent, A. E Lodolce, and A S. Pickard Bisphosphonate-Induced Osteonecrosis of the Jaw Ann. Pharmacother., February 1, 2007; 41(2): 276 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Grey and T. Cundy Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med, November 21, 2006; 145(10): 791 - 791. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boyde Jaw Bone Necrosis and Bisphosphonates: Microanatomical Questions IBMS BoneKEy, September 1, 2006; 3(9): 19 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Nase and J. B. Suzuki Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc, August 1, 2006; 137(8): 1115 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Dental Association Council on Scientific Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc, August 1, 2006; 137(8): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, et al. Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma Mayo Clin. Proc., August 1, 2006; 81(8): 1047 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Blank BISPHOSPHONATES J Am Dent Assoc, May 1, 2006; 137(5): 584 - 584. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lasser MORE ABOUT BON J Am Dent Assoc, April 1, 2006; 137(4): 441 - 441. [Full Text] [PDF]
|
|
|
|
|
|
N. W. Herrod BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS J Am Dent Assoc, April 1, 2006; 137(4): 439 - 439. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
